The FDA has classified recent submissions as a major amendment pushing the approval to its NDA for TransCon CNP back three months to February 28, 2026
The oral, film-coated tablet is licensed for patients whose cancer has returned during or shortly after hormone therapy
Abdomen-pelvis CT is the nation’s highest-volume CT category
The receipt of this order further strengthens the company's position in the global pharmaceutical market
The audit was completed with zero critical and zero major observations
Pharmaplan brings a pan-European footprint of locations and specialist teams, now operating within Exyte’s Biopharma & Life Sciences division
Subscribe To Our Newsletter & Stay Updated